L12.0
Conditions
Interventions
Group 1: The study is based on the accurate serological characterization of bullous pemphigoid patients (going beyond routine diagnostics). Based on these results, the included patients will be divide
Sponsors
Department of Dermatology University Hospital, Ruprecht-Karls-University Heidelberg
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Clinic compatible with bullous pemphigoid - Positive direct immunofluorescence findings (linear IgG and/or C3 deposition). - Depending on the subcollective, positive or negative commercial BP180, respectively BP230 ELISA. - Initial diagnosis of bullous pemphigoid
Exclusion criteria
Exclusion criteria: - Lack of legal capacity - Lack of consent - Correctional system - Patients <18 years - Pregnancy/nursing period - Evidence of linear IgA or IgM pattern in direct immunofluorescence. - Bullous pemphigoid-associated therapy within the past 6 months (except local class 1 or 2 steroid therapy for less than 7 days). - Predominant or isolated mucosal involvement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to disease control (3 days no new skin lesions). Observation period 30 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Extent of disease (BPDAI score, BPDAI pruritus component), recurrence rate, quantification of epitope-spreading phenomena in case of recurrence. 1 year observation period after initial diagnosis. | — |
Countries
Germany
Contacts
Public ContactKatharina Kommoss
Universitäts-Hautklinik Heidelberg
Outcome results
None listed